• Angelini Ventures joins top-tier investor syndicate
• Investment will fund Phase 1b studies evaluating Therini Bio’s lead candidate, THN391, for the treatment of Alzheimer’s Disease (AD) and Diabetic Macular Edema (DME), as well as support development of a fibrin/VEGF bispecific
• Investment demonstrates Angelini's continued strategic focus in neurodegenerative disease
  
  

Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and Digital Health, today announces its participation in a $39 million extension of the Series A financing round for Therini Bio, a US-based clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction.

Angelini Ventures joins a syndicate of top-tier international healthcare investors in Therini Bio, including new investor Apollo Health Ventures and existing investors SV Health Investors’ Biotech Fund and the Dementia Discovery Fund, Dolby Family Ventures, Eli Lilly and Company, Foundation for a Better World, MRL Ventures Fund and Sanofi Ventures. This latest close brings the total raised by Therini Bio, in its Series A round – first announced in April 2023 – to $75 million.

This investment builds on Angelini Ventures’ expertise in neurodegeneration, following its recent investments in Neumirna Therapeutics and Arclight Therapeutics.

The funds raised by Therini Bio through its extended Series A financing will enable the company to advance Phase 1b studies evaluating its lead candidate, THN391, a potential first-in-class monoclonal antibody designed to selectively block fibrin-mediated neuroinflammation, for the treatment of Alzheimer’s Disease (AD) and Diabetic Macular Edema (DME), as well as support development of a fibrin/VEGF bispecific.

Thomas Thestrup, Ph.D., Senior Principal at Angelini Ventures and deal lead, said “We are proud to support Therini Bio’s mission to address the underlying vascular and inflammatory drivers of neurodegenerative disease through a truly novel approach. As an active investor in companies developing next-generation treatments for neurodegenerative and other CNS disorders, we are excited about Therini Bio’s first-in-class selective antibody therapy targeting fibrin-mediated inflammation, offering a groundbreaking path to transform the treatment of diseases such as Alzheimer’s and Diabetic Macular Edema.”

Fabrizio Calisti, M.D., Medical Director at Angelini Ventures, will join Therini Bio’s Board of Directors as a Board Observer.

Tara Nickerson, Ph.D., Chief Executive Officer of Therini Bio, said “We are deeply grateful to partner with such a distinguished investor group, both new and old. Their support enables us to significantly advance our shared vision of delivering patients a rational, innovative approach to potentially treat their debilitating conditions, including AD and DME. We look forward to advancing the Phase 1b trials to demonstrate the benefit of this novel mechanism in patients.”